Physician profile
Marcus Lemoncelli
NPI 1164298410
$1,260.97
in general payments reported to CMS, 2019-2025
18 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $95.89 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $285.26 | 2024-2025 | Fanapt |
| Abbvie INC. | $157.94 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $113.49 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $107.15 | 2024-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $101.40 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $88.01 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $71.74 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $63.20 | 2025 | Auvelity |
| Exact Sciences Corporation | $45.68 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $36.21 | 2024-2025 | Dexcom G6 Transmitter |
| Indivior INC. | $35.11 | 2025 | Sublocade |
| Biogen, INC. | $33.01 | 2025 | Leqembi |
| Lilly USA, LLC | $28.21 | 2025 | Mounjaro, Zepbound |
| Luye Pharma (USA) Ltd. | $23.45 | 2025 | Erzofri Extended-Release |
| Eisai INC. | $22.49 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.40 | 2025 | Caplyta |
| Lundbeck LLC | $13.85 | 2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $13.37 | 2024 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Lemoncelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.